Fluid delivery device with sensor

Information

  • Patent Grant
  • 11724027
  • Patent Number
    11,724,027
  • Date Filed
    Wednesday, May 27, 2020
    3 years ago
  • Date Issued
    Tuesday, August 15, 2023
    9 months ago
Abstract
A wearable drug delivery device for monitoring unintended over-delivery and/or under-delivery of a stored liquid drug are provided. An absolute pressure sensor can be positioned within the fluid path of the drug delivery device. The absolute pressor sensor can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (gage or pumping pressure). Based on the detected pressures, the effects of external ambient pressure on air with the fluid path can be determined during both intended drug delivery events and unintended drug delivery events. In turn, under-delivery and/or over-delivery of the liquid drug can be determined. Based on the severity of the determined under-delivery or over-delivery of the liquid drug, alarms indicating different urgencies can be provided to the user.
Description
TECHNICAL FIELD

Embodiments generally relate to medication delivery. More particularly, embodiments relate to wearable drug delivery devices configured to monitor medication flow.


BACKGROUND

Drug delivery devices (e.g., infusion devices or pumps) can experience conditions that can lead to under-delivery or over-delivery of an infusate into a patient. For example, blockages in a fluid path (e.g., as caused by an occlusion) can cause a backup of fluid within the pump and a subsequent increase in fluid path pressure. When a blockage clears, the pressurized infusate can be delivered in a single bolus in an undesirable or unintended manner.


When air is trapped in the fluid path, changes in atmospheric pressure can cause the trapped air to expand or compress and to displace (e.g., by suction) fluid into or out of the patient. These situations can also cause under-delivery or under-delivery of the infusate into the patient. Swimming or flying are examples of common activities engaged in by a patient that can result in under-delivery and over-delivery without the patient's knowledge.


Additionally, when air is trapped in the fluid path, changes in ambient temperature can also cause the trapped air to expand or compress and to displace fluid into or out of the patient. Similarly, these situations can also cause under-delivery or over-delivery of the infusate into the patient. Swimming in the ocean or swimming in an unheated pool or using a heated blanket are examples of common activities engaged in by a patient that can result in under-delivery and over-delivery of the infusate without a patient's knowledge.


Many conventional drug delivery devices including infusion devices or pumps detect occlusions by monitoring the time it takes for the pump to actuate. This conventional approach can produce erroneous results based on variabilities within the drive system (e.g., due to friction, power sagging, mechanical variability of parts, etc.).


Even conventional systems that directly measure the pressure within the pump fluid path often do not detect changes in atmospheric pressure which can lead to over-delivery and under-delivery. These conventional systems typically utilize pressure sensors which measure pressure relative to atmospheric pressure and are incapable of detecting any change in atmospheric pressure which can lead to over-delivery and under-delivery without a patient's knowledge as described above.


Accordingly, what is needed is a drug delivery device with improved capabilities for detecting under-delivery and over-delivery conditions during intended delivery periods or unintended delivery periods that can be caused by a variety of factors including changes in atmospheric pressure.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a first exemplary pump system.



FIG. 2 illustrates a second exemplary pump system incorporating a pressure sensor.



FIG. 3 illustrates a block diagram of operations performed by the pump system of FIG. 2.



FIG. 4 illustrates a third exemplary pump system incorporating a flow sensor.



FIG. 5 illustrates a block diagram of operations performed by the pump system of FIG. 4.



FIG. 6 illustrates an exemplary drug delivery device.



FIG. 7 illustrates a first exemplary incorporation of a pressure sensor into the drug delivery device of FIG. 6.



FIG. 8 illustrates a second exemplary incorporation of a pressure sensor into the drug delivery device of FIG. 6.



FIG. 9 illustrates a third exemplary incorporation of a pressure sensor into the drug delivery device of FIG. 6.



FIG. 10 illustrates a fourth exemplary incorporation of a pressure sensor into the drug delivery device of FIG. 6.



FIG. 11 illustrates a second view of the exemplary drug delivery device of FIG. 6.





DETAILED DESCRIPTION

This disclosure presents various systems, components, and methods related to a drug delivery device. Each of the systems, components, and methods disclosed herein provides one or more advantages over conventional systems, components, and methods.


Various embodiments include a wearable drug delivery device having a pump system. The pump system can be used to deliver a stored liquid drug or other therapeutic agent to a user or patient. An absolute pressure sensor can be positioned within the fluid path of the drug delivery device and/or pump system. The absolute pressor sensor can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (gage or pumping pressure). Based on the detected pressures, the effects of external ambient pressure on air with the pump system and/or fluid path can be determined during intended drug delivery events and unintended drug delivery events. In turn, under-delivery and/or over-delivery of the liquid drug can be determined. Based on the severity of the determined under-delivery or over-delivery of the liquid drug, alarms of different urgencies can be provided to the user. Other embodiments are disclosed and described including various embodiments directed to the use of a flow sensor to detect the aforementioned over-delivery and under-delivery conditions.


Various embodiments provide techniques for monitoring the absolute and relative pressures associated with a liquid drug pump system of a wearable drug delivery device. Based on the monitored pressures, an amount (e.g., corresponding to an over-delivery or an under-delivery) and direction (e.g., into or out of the pump system) of unintended liquid drug flow can be determined. If the amount of the unintended liquid drug exceeds one or more thresholds, one or more associated alarms can be provided to a user. Monitoring can be provided during intended drug delivery operations when the pump system is directed to provide the liquid drug to the user and during unintended drug delivery operations when the pump system is directed to not provide the liquid drug to the user. Other embodiments are disclosed and described.


The pressure sensor 202 can be an absolute pressure sensor that can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (e.g., gage or pumping pressure) introduced as the pump system 200 displaces fluid (e.g., the infusate stored in the reservoir 102) in the overall fluid path of the pump system (e.g., including the reservoir 102 and the fluid path component 106). By using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of external ambient pressure on air within the reservoir 102. Further, by using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of the internal pumping pressure changes due to pumping (e.g., expelling the infusate from the reservoir 102 for delivery to the patient). By measuring these effects, the pump system 200 can detect situations of possible over-delivery and/or under-delivery of the infusate to the patient due to both intended and unintended actions (e.g., during periods of intended delivery and periods of unintended delivery). Further, the pump system 200 can provide indications of such over-delivery and/or under-delivery conditions or situations to the patient, allowing the patient to respond accordingly.



FIG. 1 illustrates a pump system that can be used to deliver an infusate to a patient. The pump system can include a reservoir 102, a plunger 104, a fluid path component 106, a supporting mechanical structure or component 108, and a plunger or pump drive mechanism 110. The reservoir 102 can store or hold the infusate. The infusate can be any liquid drug and/or therapeutic agent. The plunger 104 can be used to expel the infusate from the reservoir 102 for delivery to a patient or user. The reservoir 102 can be coupled to the fluid path component 106. The fluid path component 106 can be coupled to the patient.


The supporting mechanical structure 108 can provide structural support to the reservoir 102, the fluid path component 106, and/or the plunger drive mechanism 110. The supporting mechanical structure 108 is not limited to the presentation depicted in FIG. 1. The supporting mechanical structure 108 can encase, surround, or otherwise provide structural support for the reservoir 102, the fluid path component 106, and/or the plunger drive mechanism 110. The plunger drive mechanism 110 can be any mechanical or electromechanical system that can advance the plunger 104 into the reservoir 102. As the plunger drive mechanism 110 is operated and the plunger 104 advances into the reservoir, the infusate can be expelled from the reservoir 102 and provided to the patient by way of the fluid path component 104. The fluid path component 106 can include or can be coupled to a needle or cannula providing access (e.g., via an outlet) to the patient.


The pump system shown in FIG. 1 can be part of a drug delivery device. As an example, the pump system can be part of a wearable drug delivery device. In various embodiments, the pump system can be used to deliver insulin to a patient. The pump system can be considered to be an infusion pump system. The overall fluid path of the pump system shown in FIG. 1 can include the reservoir 102 as well as the fluid path component 106 that couples the reservoir 102 to the patient.


During periods of operation—for example, when the pump system of FIG. 1 is specifically directed to deliver a portion of the infusate to the patient—the pump system can erroneously over-deliver or under-deliver a desired amount of infusate to the patient. Under-delivery and over-delivery can be caused by a variety of factors including changes in atmospheric pressure, changes in ambient temperature, and occlusions in the fluid path. Further, during periods of unintended delivery—for example, when the pump system of FIG. 1 is specifically directed not to deliver any infusate to the patient—these factors can still cause delivery of unintended amounts of the infusate to the patient (or backflow of the infusate).


The pump system shown in FIG. 1 does not include any capability to detect and monitor any over-delivery or under-delivery of the infusate during intended delivery periods or unintended delivery periods. The pump system of FIG. 1 is further unable to account for any such under or over-delivery condition and is incapable of notifying the patient as to any under or over-delivery condition. Consequently, operation and of the pump system of FIG. 1 can be inefficient and even hazardous to the patient.



FIG. 2 illustrates a pump system 200 (or infusion pump system 200) for providing monitoring of any over-delivery or under-delivery condition during any intended or unintended drug delivery. As shown in FIG. 2, the pump system 200 can include the reservoir 102, the plunger 104, the fluid path component 106, the supporting component 108, and the plunger drive mechanism 110. The pump system 200 can further include a pressure sensor 202 and a monitoring component 204. The pump system 200 can, among other features, detect flow (e.g., unintended flow) of the infusate through pressure sensing as described herein.


The pressure sensor 202 can be an absolute pressure sensor that can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (e.g., gage or pumping pressure) introduced as the pump system 200 displaces fluid (e.g., the infusate stored in the reservoir 102) in the overall fluid path of the pump system (e.g., including the reservoir 102 and the fluid path component 106). By using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of external ambient pressure on air within the reservoir 102. Further, by using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of the internal pumping pressure changes due to pumping (e.g., expelling the infusate from the reservoir 102 for delivery to the patient). By measuring these effects, the pump system 200 can detect situations of possible over-delivery and/or under-delivery of the infusate to the patient due to both intended and unintended actions (e.g., during periods of intended delivery and periods of unintended delivery). Further, the pump system 200 can provide indications of such over-delivery and/or under-delivery conditions or situations to the patient, allowing the patient to respond accordingly. This enables a drug delivery device that incorporates the pump system 200 to operate more effectively and safely and to provide an improved experience for the patient.


In various embodiments, the pressure sensor 202 can be integrated into the reservoir 102 as shown in FIG. 2. In various embodiments, the pressure sensor 202 can be integrated anywhere along the overall fluid path of the pump system 200 (e.g., including the reservoir 102 and/or the fluid path component 106) that is at the same approximate pressure as the outlet into the patient. An intervening membrane (not shown in FIG. 2 for simplicity) can be used to isolate the pressure sensor 202 from the infusate within the reservoir 102 and/or fluid path component 106. Alternatively, a pliable gel or sufficiently soft rubber can be used to isolate the pressure sensor 202 from the infusate.


In various embodiments, the pressure sensor 202 can have a round body to simplify sealing against the reservoir 102 and/or the fluid path component 106. In various embodiments, an integral lip seal can be used to seal the interface between the body of the pressure sensor 202 and the reservoir 102 and/or fluid path component 106.


The pressure sensor 202 can be coupled to a monitoring component 204. The pressure sensor 202 can measure the absolute pressure of the reservoir 102 and/or the fluid path component 106 (e.g., the overall fluid path of the pump system 200) and can provide an output signal to the monitoring component 204. In various embodiments, the pressure sensor 202 can take continuous readings of the absolute pressure. The output signal from the pressure sensor 202 can indicate the measured or detected absolute pressure and/or any other measured, detected, or derived pressure value.


The monitoring component 204 can process the received signal from the pressure sensor 202. The monitoring component 204 can be implemented in hardware, software, or any combination thereof. In various embodiments, the monitoring component 204 can be implemented using a processor and associated memory and can execute one or more monitoring algorithms or processes as described herein. In various embodiments, the monitoring component 204 can be implemented as dedicated hardware (e.g., as an application specific integrated circuit (ASIC)). The monitoring component 204 can be a constituent part of the pump system 200, can be implemented in software as a computational model, or can be implemented external to the pump system 200 (e.g., remotely).


In various embodiment, the output signal generated by the pressure sensor 202 can be a voltage signal, a current signal, and/or an electrical charge signal. In various embodiment, the output signal generated by the pressure sensor can be a data signal (e.g., an analog or digital data signal) such as, for example, an inter-integrated circuit (I2C), serial peripheral interface (SPI), or any other known or customized synchronous or asynchronous data communication stream. In general, the output signal from the pressure sensor 202 can indicate a measured pressure. Further, the pressure sensor 202 and the monitoring component 204 can communicate over any known signaling protocol or standard including any known wired or wireless communication or signaling protocol. In various embodiments, the signal generated by the pressure sensor 202 for output and delivery to the monitoring component can be temperature compensated to remove or mitigate any error due to temperature changes. The monitoring component 204 can convert the signal received from the pressure sensor 202 into an indication of absolute pressure (e.g., pounds per square inch absolute (psia)).


The monitoring component 204 can generate a characterization of the fluid capacitance of the reservoir 102 and/or the fluid path component 106 (e.g., a model of the fluid capacitance of the overall fluid path of the pump system 200). Alternatively, the monitoring component 204 can be provided such information. For example, the monitoring component 204 can include a memory component or can access a memory component storing such information. In various embodiments, one or more components (e.g., external hardware components) can be used to generate characterizations of the fluid path fluid capacitance that can be provided to the monitoring component 204 in the form of data that can be stored, or integrally included as part of operational software. The characteristic fluid capacitance can be an input into a detection algorithm or monitoring process implemented by the monitoring component 204. The fluid capacitance can be considered to be the relationship between an internal pressure of the reservoir 102 and/or the fluid path component 106 (e.g., the overall fluid path of the pump system 200) and the volume of fluid necessary to achieve the specific pressure.


As will be appreciated by a person of ordinary skill in the art, the nature of fluid capacitance is roughly equivalent to electrical capacitance in which the infusate acts as electrical charge, internal gage pressure behaves as the positive voltage in an electrical circuit, the hydraulic stiffness of a fluid path acts as the electrical capacitance of a capacitor, and the fluid path outlet flow restriction acts as a resistor does in the electrical equivalent. Additionally, counter infusion pressure provided by the patient at the infusion site acts as the ground potential. Further, when counter-infusion pressure matches the infusion pressure, flow (e.g., to the patient) stops. If counter-infusion pressure exceeds internal gage pressure, counter flow (flow into the fluid path of the pump system 200 and away from the patient) can occur.


The fluid capacitance can be characterized using a numeric value, or a range of numeric values, or a variable model which defines the characteristic fluid capacitance of the overall fluid path of the pump system 200. In various embodiments, a memory associated with the monitoring component 204 can store values for characterizing the fluid capacitance associated with the pump system 200. In various embodiments, the one or more stored values can be based on characterization of the specific design of the pump system 200.


As the pump system 200 operates to expel the infusate from the reservoir 102 and into the fluid path component 106 for delivery to the patient, the fluid capacitance associated with the pump system 200 can change. For example, the fluid capacitance can change based on changes to the effective stiffness of the reservoir 102 as the plunger 104 is advanced further into the reservoir 102 by the plunger drive mechanism 110. As another example, changes in the stiffness of the supporting mechanical structure 108, the pump drive mechanism 110, or the interfaces between these components can cause the fluid capacitance to change. Accordingly, the monitoring component 204 can include a range of characterized fluid capacitance values that account for any such change. In various embodiments, the monitoring component 204 can be configured to use a function or other mathematical model capable of defining the change in fluid capacitance over the range of operation of the pump system 200—for example, from fully filled to empty. Based on an indication of the fluid capacitance—for example, by generating an estimate of the fluid capacitance over time as the pump system 200 operates—the monitoring component 204 can detect and determine, for example, any under-delivered fluid based on an indication of pressure provided by the pressure sensor 202.


By monitoring the absolute pressure within the fluid path of the pump system 200, the amount and direction of flow from the fluid path of the pump system 200 can be determined by the monitoring component 204. Based on determined changes in the pressure of the fluid path of the pump system 200, and the characteristic fluid capacitance of the fluid path of the pump system 200, a total net flow of fluid (e.g., the infusate) from a first point in time to a later, second point in time can be determined. Based on the amount and direction of flow error over time (e.g., unintended or undesired flow of the infusate into or out of the fluid path of the pump system 200), the monitoring component 204 can determine if an alert or other alarm should be issued to the patient.


During operation of the pump system 200, as the plunger 104 advances further into the reservoir 102, the fluid capacitance associated with the pump system 200 can change and the pressure associated with the pump system 200 can also change. The monitoring component 204, by monitoring the pressure and fluid capacitance of the pump system 200 over time, can determine net fluid flow over time—either intended or unintended and either into or out of the pump system 200 (or a drug delivery device in which the pump system 200 can be included). In various embodiments, to estimate an amount of fluid flow, the monitoring component 200 can estimate an amount of undelivered volume of fluid (e.g., the infusate within the fluid path or reservoir 102) at two different points in time.


Accordingly, based on data or information provided by the pressure sensor 202, the monitoring component 204 can monitor an amount of infusate delivered over time to determine if the amount is a proper or correct amount based on a predetermined level of intended infusate delivery. The monitoring component 204 can further determine if changes in physical conditions or the environment in which the pump system 200 operates can lead to under-delivery or over-delivery of the infusate during periods of delivery or non-delivery. The flow direction and the amount of fluid as determined by the monitoring component 204 can be compared to one or more operational thresholds, to determine if an alert should be issued to the patient. This allows the patient to more safely use the pump system 200 and to take corrective action if necessary.


In various embodiments, the pump system 200 and/or the monitoring component 204 can operate to monitor the following operational conditions (e.g., errors) associated with the pump system:

    • 1. Deviation in total infusate delivered (e.g., from a desired level of infusate to be delivered) during an intended delivery period/delivery operation;
    • 2. Deviation in total infusate delivered over time from unintended delivery/non-intended delivery operation; and


Further, in various embodiments, the pump system 200 and/or the monitoring component 204 (and/or a drug delivery device of which the pump system 200 can be a component) can operate to provide the following alarms as necessary based on monitoring flow direction and amount of flow:

    • 1. Under-delivery of the infusate during pumping—can be caused by, for example, a partial occlusion in the fluid path of the pump system 200, increased back pressure, and/or decreased site viability;
    • 2. No delivery of the infusate during pumping—can be caused by, for example, a full occlusion in the fluid path of the pump system 200 and an alarm can alert the patient to immediately replace the drug delivery device in which the pump system 200 operates;
    • 3. Potential back-flow into pump system 200 delaying delivery—can be caused by, for example, ambient pressure changes from low pressure to high pressure (e.g., during landing in a flight); and
    • 4. Potential out-flow from pump system 200 without pumping—can be caused by, for example, ambient pressure changes from high pressure to low pressure (e.g., during take-off in a flight).


For the first source of error listed above (i.e., deviation of total infusate delivered over time from intended delivery), the monitoring component 204 can monitor (e.g., continuously) the pressure in the fluid path of the pump system 200 from the start of an intended delivery event until the end of the intended delivery event during which, for example, a predetermined or desired amount of infusate is to be delivered. The monitoring component 204 can then compare the difference in the determined pressures (or the volume of undelivered fluid) to predetermined delivery thresholds. If the amount of infusate delivered is more than desired or intended, and exceeds a first threshold, then an alert or alarm can be provided to the user. If the amount of infusate delivered is less than desired or intended, and is less than a second threshold, then an alert or alarm can similarly be provided to the user. In this way, a patient can be made aware of under-delivery or over-delivery situations through pressure monitoring that enables flow amounts and directions to be determined.


In various embodiments, the alerts or alarms can be visual and/or audible and can include haptic and/or tactile feedback such as vibrational movement of the drug delivery device. Further, in various embodiments, the alarms can vary based on the type of alarm—for example, a first type of visual and/or audible alert for an over-delivery condition and a second, different visual and/or audible alert for an under-delivery condition. If the over or under-delivery condition stays within the set thresholds, then an alarm may not be provided (e.g., if the deviation from a desired delivery is minimal). Further, multiple thresholds can be established and compared such that more significant deviations from an intended delivery can trigger heightened alarm signals or indications or the patient.


In various embodiments, the thresholds can be dynamically adjusted. For example, the thresholds for comparison can be adjusted based on a de-rating factor that can be based on the total delivered amount of infusate and/or the current unmetabolized excess infusate remaining in the blood stream in the event of an over-delivery event. In various embodiments, the monitoring component 204 can determine an estimate of infusate yet to be delivered in the event of under-delivery by monitoring the capacity of fluid path pressure differential from the start of infusion.


In various embodiments, the monitoring component 204 can distinguish changes in pressure due to ambient (atmospheric) pressure changes from intended pumping pressure changes. In various embodiments, the monitoring component 204 can implement various filtering techniques including, for example, Bayesian nonlinear filters such as Kalman and/or particle filters to isolate and then compensate for random wandering pressure changes due to, for example, changing weather conditions. The monitoring component 204 can also employ band pass filtering to isolate pulsatile pumping pressure changes.


Atmospheric pressure can change with geographic location (e.g., altitude) as well as weather. Accordingly, the monitoring component 204 can include a rolling window filter for establishing or re-establishing a baseline atmospheric pressure. This baseline atmospheric pressure level can be used for comparison over any time period. In various embodiments, the baseline filter window implemented by the monitoring component 204 can be linked to the metabolization rate of the infusate when known which can be provided to the monitoring component 204.


As described above, the monitoring component 204 can include one or more thresholds and associated alarms that can be issued to a user. Further, as described above, multiple threshold levels and heightened alerts can be used for comparison to indicate an escalating intensity of alarm based on the degree of risk associated with any particular threshold being exceeded or not met—for example, based on the level of infusate delivery missed or the level of excessive infusate delivery.


In various embodiments, in the case of little to no delivery (e.g., due to an occlusion), thresholds can be set based on the specific risk of the infusate via a table of values stored in a memory (e.g., ROM and/or RAM memory or any other memory or look-up table) associated with the monitoring component 204


For the second source of error listed above (i.e., deviation of total infusate delivered over time from unintended delivery), the following can be contributing sources for any such deviation or error:

    • 1. Expansion or contraction of air within the fluid path of the pump system 200 due to ambient pressure or temperature changes;
    • 2. Physical compression of the fluid path of the pump system 200;
    • 3. Unintended operation of the plunger 104 and/or pumping mechanism of the pump system 200;
    • 4. Mechanical errors (e.g., incorrect drive train multiplier, thread errors, or cam errors); and
    • 5. Siphoning due to air leaks in the fluid path of the pump system 200.


In various embodiments, the monitoring component 204 can monitor (e.g., sample) the pressure of the fluid path of the pump system 200 continuously (or semi-continuously to conserve power) during periods of intended non-delivery—that is, during times when the pump system 200 is not being directed to specifically provide the infusate to the patient. During these periods, the internal pressure of the fluid path of the pump system 200 is unlikely to change by more than an expected amount due to the narrow range of atmospheric pressure changes. By monitoring the fluid path pressure of the pump system 200, the monitoring component 204 can determine if any such changes in pressure are significant.


In situations where the atmospheric pressure can change by an amount more than an expected amount due to normal weather based atmospheric pressure (e.g., during flying on a commercial flight), the monitoring component 204 can determine the potential unintended delivery due to air expansion in the reservoir 104 and can alert the user to any potential risk associated with such determined unintended delivery. Additionally, the monitoring component 204 can alert the user of the opposite condition (e.g., back flow) that may occur following an increase in absolute pressure as would be experienced during normalization of aircraft cabin pressure upon landing during a flight.


Further, in situations where the atmospheric pressure can change by an amount more than an expected amount due to normal weather based atmospheric changes, but at a rate which is lower than typical air travel pressure changes (e.g., traversing altitude slowly as can happen when driving from a lower altitude to a higher altitude), the monitoring component 204 can determine the rate of change of atmospheric pressure. The monitoring component 204 can use this determined rate to properly adjust the intensity of alerts and/or alarms provided to the patient.


Overall, the monitoring component 204 can monitor pressure changes during periods of non-delivery (e.g., intended non-delivery) to determine if any fluid is unintentionally provided to the patient or being removed from the fluid path coupled to the patient. If the levels of unintended delivery exceed one or more thresholds during such periods, one or more associated alarms (e.g., of heightened intensity) can be provided to the user.


In various embodiments, the monitoring component 204 can use a rolling window low pass filter matched to the in vivo decay rate of the infusate within the patient's body, or based on a reasonable threshold which can be set by the user. Additional filtering techniques can be employed in other embodiments utilizing Kalman, particle, or non-linear filtering techniques.


In various embodiments, the pump system 200 can include a temperature sensor to alter the sampling frequency in response to the potential for expansion or contraction of air bubbles in the fluid path of the pump system 200. For example, if greater temperature swings are to be expected within the environment in which the pump system 200 operates, larger pressure swings may be expected to occur. Accordingly, monitoring and/or sampling of the pressure may be adjusted during such time periods to increase monitoring or sampling. The temperature sensor can be part of or can be coupled to the monitoring component 204 to provide a measure of temperature to the monitoring component 204.



FIG. 3 illustrates an operational block diagram 300 that shows operations for providing monitoring of any over-delivery or under-delivery condition during any intended or unintended drug delivery based on the pressure sensing described herein.


The operational block diagram 300 illustrates components that can be implemented by or can be included within the monitoring component 204 when implemented in conjunction with the pressure sensor 202. The operational block diagram 300 illustrates the inputs and outputs of each component and the function or capabilities of each components. The operations and components shown can be implemented in hardware, software, or any combination thereof.


The operational block diagram 300 can include the following components: a calibration-compensation-conversion component 302, a delivery error estimation component 304, a delivery error tracking and alarm determination 306, an ambient pressure model component 308, an intended delivery model 3108, a time-based decay alert-alarm parameter storage component 312, and an alert-alarm actuator component 314. The operations and functionalities of these components are described below.


The calibration-compensation-conversion component 302 can be coupled to a pressure sensor (e.g., the pressure sensor 202) and can receive one or more signals from the pressure sensor as described above. The calibration-compensation-conversion component 302 can also receive one or more signals relating to calibration, conversion, or compensation parameters. The calibration-compensation-conversion component 302 can operate to determine and output fluid path pressure (e.g., psi) based on the signals from the pressure sensor. Accordingly, the calibration-compensation-conversion component 302 can output a fluid path pressure signal. The calibration, conversion, or compensation parameters can also operate to provide sensor calibration and/or compensation functions such as, for example, linearization of output, input/output offset correction, and/or temperature compensation.


The delivery error estimation component 304 can receive the fluid path pressure output signal from the calibration-compensation-conversion component 302. The delivery error estimation component 304 can also receive fluid capacitance values (e.g., system calibration values) and baseline pressure values as shown in FIG. 3. The delivery error estimation component 304 can operate to determine instantaneous volumetric delivery error (e.g., an amount of under-delivery or over-delivery) and can output a signal indicating the same. To determine the instantaneous volumetric delivery error, the delivery error estimation component 304 can transform the provided pressure level relative to the pressure baseline into a delivery error by multiplying the pressure difference by the provided fluid capacitance value.


In various embodiments, to determine instantaneous volumetric delivery error, which can be represented as Verror(t), where “t” represent time, the delivery error estimate estimation component 304 can utilize a fluid capacitance value or values, which can be represented as Cfluid(ξ,t). Fluid capacitance is typically expressed in units of volume/pressure (e.g., in μL/psi for small pumping devices). “ξ” can represent an aggregated variability of the fluid capacitance which can vary both with time and with any number of system physical parameters (e.g., specific to each pumping device). The baseline ambient pressure, represented as P0(t), can be the baseline pressure at which the system is operating at any given time as provided by the ambient pressure model 308. The instantaneous fluid path pressure provided by the calibration-compensation-conversion component 302, represented as P(t), can be the instantaneous pressure measured at a given time. The instantaneous volumetric delivery error can therefore be expressed as: Verror(t)=[P(t)−P0(t)]*Cfluid(ξ,t).


The delivery error tracking and alarm determination component 306 can receive the instantaneous volumetric delivery error signal outputted by the delivery error estimation component 304. The delivery error tracking and alarm determination component 306 can also receive time-based de-rating factors, an ambient pressure model error, and an indication of intended volumetric delivery as shown in FIG. 3. Based on these input signals, the delivery error tracking and alarm determination component 306 can generate an alert or alarm signal as necessary, as described above. The delivery error tracking and alarm determination component 306 can compare the intended volumetric delivery against the sum of ambient pressure model error and instantaneous volumetric delivery error as modified by time-based de-rating factors. Threshold comparisons can also be made to determine if an alarm signal should be generated. If an alarm condition is determined, a signal indicating the same can be generated and outputted.


The ambient pressure model 308 can receive the fluid path pressure signal from the calibration-compensation-conversion component 302. The ambient pressure model 308 can output an ambient pressure model error. The ambient pressure model 308 can track background ambient pressure changes to limit false alarms due to ambient pressure or back pressure changes. The ambient pressure model 308 can also track background ambient pressure changes to determine over-delivery and/or under-delivery due to significant pressure excursions.


The intended delivery model component 310 can receive pump control data (e.g., a count of the number of pulses delivered) and can receive pump characteristic performance data (e.g., a measure of volume per pulse delivery). The intended delivery model component 310 generate an indication of expected volumetric delivery as shown in FIG. 3. The intended delivery model component 310 can track the expected delivery as commanded by the pump system for comparison in the delivery error tracking and alert-alarm determination component 306.


The time-based decay alert-alarm parameter storage 312 can receive and/or store system alert-alarm decay parameters. The time-based decay alert-alarm parameter storage 312 can output specific mathematical functions to de-rate the impact of instantaneous volumetric error over time. The time-based decay alert-alarm parameter storage 312 can ensure transient unintended delivery events do not accumulate in the system and lead to unnecessary alarms.


The alert-alarm actuator 314 can receive any alert-alarm signal from the delivery error tracking and alarm determination component 306. Based upon receipt of any alert-alarm signal, the alert-alarm actuator 314 can activate an alarm mechanism or component as described above including, for example, a visual, tactile, and/or audible alarm to notify the user of an urgent condition.



FIG. 4 illustrates a pump system 400 (or infusion pump system 400) for monitoring of any over-delivery or under-delivery condition during any intended or unintended drug delivery. As shown in FIG. 4, the pump system 400 can include the reservoir 102, the plunger 104, the fluid path component 106, a flow sensor 402, and the monitoring component 204. The pump system 400 can, among other features, detect unintended flow through flow sensing as described herein.


In contrast to the operation of the pump system 200 which can detect pressure and subsequently determine flow based on fluid capacitance of the fluid path of the pump system 200, the pump system 400 uses a flow sensor 402. The flow sensor 402 can be positioned directly in the flow path of the pump system 400 (e.g., in the fluid path component 106 as shown in FIG. 4). In various embodiments, the flow sensor 402 can sense flow (e.g., flow of the infusate) out of and into the fluid path of the pump system 400.


In general, the flow sensor 402 can be positioned anywhere along the fluid path of the pump system 400 including in a cannula coupled to the end of the fluid path component 106 leading to the patient. In various embodiments, the flow sensor 402 can be located just outside the reservoir 102 and before the hard cannula providing access to the patient. In various embodiments, the flow sensor 402 can be integrated into the hard cannula.


A variety of different types of flow sensors can be used for the flow sensor 402 such as, for example, a micro-electro-mechanical system (MEMS) thermal mass flow sensor, a paddle wheel, or other type flow sensor appropriately sized for the expected flow from the intended pumping action of the pump system 400 and/or the effect of ambient pressure changes on air trapped within the fluid path of the pump system 400.


The flow channel for the flow sensor 402 can be made from a variety of materials including, for example, glass, metal, or any other material that can provide adequate thermal conductance to detect changes in the thermal gradient in the flowing media (e.g., the infusate). The flow sensor 402 can be calibrated for the specific viscosity, thermal conductance, and flow channel convective coefficient, and external thermal changes (e.g., to provide temperature compensation).


The pump system 400 can provide similar functionality as the pump system 200 with the change of a flow sensor 402 being used instead of a pressure sensor as provided for in the pump system 200. To that end, the flow sensor 402 can be coupled to the monitoring component 204 with the monitoring component 204 configured to operate in conjunction with a flow sensor. The flow sensor 402 can take regular readings of flow through the fluid path of the pump system 400 and can output a signal to the monitoring component 204. The type of signal, format, and/or protocol of the signal of the output signal can be similar to the output signal provided by the pressure sensor 202 but with providing an indication of flow rather than pressure.


The monitoring component 204 can convert the signal from the flow sensor 402 to a measure of flow rate (e.g., in units of volume/time). In various embodiments, a flow rate in units of μL/minute can be used. In general, any representation of flow magnitude can be used.


To determine total flow over a given period of time, the monitoring component 204 can integrate the flow data to compute the total net volume dispensed over a given amount of time. This value of net total delivery can then be used to monitor over-delivery and/or under-delivery conditions during operation of the pump system 400 in a manner similar to that described above in relation to the pump system 200.


Accordingly, based on data or information provided by the flow sensor 402, the monitoring component 204 can monitor an amount of infusate delivered over time to determine if the amount is a proper or correct amount based on a predetermined level of intended infusate delivery. The monitoring component 204 can further determine if changes in physical conditions or the environment in which the pump system 400 operates can lead to under-delivery or over-delivery of the infusate during periods of intended delivery or intended non-delivery. The flow direction and the amount of fluid as determined by the monitoring component 204 can be compared to one or more operational thresholds, to determine if an alert should be issued to the patient. This allows the patient to more safely use the pump system 400 and to take corrective action if necessary.


Overall, the pump system 400 can monitor the same operation conditions and errors listed above in relation to the pump system 200 and can operate to provide the alarms indicated above as necessary based on monitoring flow direction and amount of flow during delivery periods and non-delivery periods (e.g., by monitoring net flow over set intervals of time of delivery or non-delivery). Accordingly, the discussion above of these features in relation to the pump system 200 are applicable to the pump system 400.


Further, the pump system 400 can adjust sampling of flow rates during (e.g., monitoring of flow rates) during periods of non-delivery—that is, during times when the pump system 400 is not being directed to specifically provide the infusate to the patient. Sampling of flow can be made continuously or semi-continuously to conserve power. In various embodiments, the pump system 400 can include an ambient pressure sensor to alter the flow sampling frequency in response to the potential for expansion or contraction of air bubbles in the fluid path. In various embodiments, the pump system 400—similar to the pump system 200—can include a temperature sensor to alter the flow sampling frequency in response to the potential for expansion or contraction of air bubbles in the fluid path, as described above in relation to the pump system 200.



FIG. 5 illustrates an operational block diagram 500 that shows operations for monitoring of any over-delivery or under-delivery condition during any intended or unintended drug delivery based on the flow sensing described herein. The operational block diagram 500 illustrates components that can be implemented by or can be included within the monitoring component 204 when implemented in conjunction with the flow sensor 402. The operational block diagram 500 illustrates the inputs and outputs of each component and the function or capabilities of each components. The operations and components shown can be implemented in hardware, software, or any combination thereof.


The operational block diagram 500 can include the following components: a calibration-compensation-conversion component 502, a delivery error estimation component 504, a delivery error tracking and alarm determination 506, an ambient pressure model component 508, an intended delivery model 510, a time-based decay alert-alarm parameter storage component 512, and an alert-alarm actuator component 514, and an ambient pressure feedback component 516. The operations and functionalities of these components are described below.


The calibration-compensation-conversion component 502 can be coupled to a flow sensor (e.g., the flow sensor 402) and can receive one or more signals from the flow sensor as described above. The calibration-compensation-conversion component 502 can also receive one or more signals relating to calibration, conversion, or compensation parameters. The calibration-compensation-conversion component 502 can operate to determine and output fluid path flow (e.g., μL/min) based on the signals from the flow sensor. Accordingly, the calibration-compensation-conversion component 502 can output a fluid path flow signal indicating instantaneous flow rate. The calibration, conversion, or compensation parameters can also operate to provide sensor calibration and/or compensation functions such as, for example, linearization of output, input/output offset correction, and/or temperature compensation.


The delivery error estimation component 504 can receive the fluid path instantaneous flow rate output signal from the calibration-compensation-conversion component 502. The delivery error estimation component 504 can also receive fluid capacitance values (e.g., system calibration values), ambient pressure baseline values, and a clock signal (e.g., from an external clock) as shown in FIG. 5. The delivery error estimation component 504 can operate to determine instantaneous volumetric delivery error (e.g., an amount of over-delivery or under-delivery) and can output a signal indicating the same. To determine the instantaneous volumetric delivery error, the delivery error estimation component 504 can integrate indicators of fluid path flow to determine instantaneous volumetric flow error. The delivery error estimation component 504 can also compensate for ambient pressure changes which could cause unintended flow to occur.


The delivery error tracking and alarm determination component 506 can receive the instantaneous volumetric delivery error signal outputted by the delivery error estimation component 504. The delivery error tracking and alarm determination component 506 can also receive time-based de-rating factors, an ambient pressure model error, and an indication of intended volumetric delivery as shown in FIG. 5. Based on these input signals, the delivery error tracking and alarm determination component 506 can generate an alert or alarm signal as necessary as described above. The delivery error tracking and alarm determination component 506 can compare the intended volumetric delivery against the sum of ambient pressure model error and instantaneous volumetric delivery error as modified by time based de-rating factors. Threshold comparisons can also be made to determine if an alarm signal should be generated. If an alarm condition is determined, a signal indicating the same can be generated and outputted.


The ambient pressure model 508 can receive an ambient pressure signal from the ambient pressure feedback component 516. The ambient pressure model 508 can output an ambient pressure model error. The ambient pressure model 508 can track background ambient pressure changes to limit false alarms due to ambient pressure or back pressure changes. The ambient pressure model 508 can also track background ambient pressure changes to determine over-delivery and/or under-delivery due to significant pressure excursions.


The intended delivery model component 510 can receive pump control data (e.g., a count of the number of pulses delivered) and can receive pump characteristic performance data (e.g., a measure of volume per pulse delivery). The intended delivery model component 510 can generate an indication of expected volumetric delivery as shown in FIG. 5. The intended delivery model component 510 can track the expected delivery as commanded by the pump system for comparison in the delivery error tracking and alert-alarm determination component 506.


The time-based decay alert-alarm parameter storage 512 can receive and/or store system alert-alarm decay parameters. The time-based decay alert-alarm parameter storage 512 can output specific mathematical functions to de-rate the impact of instantaneous volumetric error over time. The time-based decay alert-alarm parameter storage 512 can ensure transient unintended delivery events do not accumulate in the system and lead to unnecessary alarms.


The alert-alarm actuator 514 can receive any alert-alarm signal from the Delivery error tracking and alarm determination component 506. Based upon receipt of any alert-alarm signal, the Alert-alarm actuator 514 can activate an alarm mechanism as described above including, for example, a visual and/or audible alarm to notify the user of an urgent condition.


The ambient pressure feedback component 516 can provide ambient pressure feedback (e.g., in psi) via an absolute pressure sensor (e.g., not sensing the fluid path). This ambient pressure feedback component 516 can be optional to help account for events in between flow sampling.



FIG. 6 illustrates an exemplary drug delivery device 600. The drug delivery device 600 can represent any of the drug delivery devices described herein. The drug delivery device 600 can be a wearable drug delivery device. The drug delivery device 600 can be designed to deliver any type of drug, medicine, therapeutic agent, or infusate to a user such as, for example, insulin. The drug delivery device 600 can be a single-use device (e.g., filled once and used once and then discarded) or can be a multiple-use device (e.g., filled one or more times and used after one or more fillings).


In various embodiments, the drug delivery device 100 can be provided to a user without any included drug or medicine. Under such a scenario, a user may, for example, fill a reservoir of the drug delivery device 600 with a medicine or drug (e.g., by transferring a fluid from a syringe to a reservoir of the drug delivery device 600).


The drug delivery device 600 can be an infusion device, including a drug delivery pump device as described herein. The drug delivery device 600 may provide a stored drug to a user over a relatively long period of time (e.g., over several days in small dosage amounts) or over a relatively short period of time (e.g., over a few hours to a day). In various embodiments, the drug delivery device 600 can be an OmniPod® (Insulet Corporation, Billerica, Mass.) insulin delivery device. The drug delivery device 600 can be a drug delivery device such as those described in U.S. Pat. Nos. 7,303,549, 7,137,964, or 6,740,059, each of which is incorporated herein by reference in its entirety.


In various embodiments, the drug delivery device can include the pump systems described herein including the pump system 200 or the pump system 400 as well as the corresponding implementations of the monitoring component 204 described in relation to FIGS. 3 and 5, respectively. Overall, the drug delivery device 100 can include the monitoring of over-delivery and under-delivery of an infusate to a patient during intended delivery periods and intended non-delivery periods according to the techniques described herein.


Various internal constituent components of the drug delivery device 600 are shown in FIG. 6. A top or cover of the drug delivery device 600 is not shown so as to provide a view of the various internal components and features of the drug delivery device 600. As shown in FIG. 6, the drug delivery device 600 can include a reservoir or pump reservoir 602, a reservoir inlet 604, a reservoir outlet 606, a sensor 608, a sensor assembly 610, a printed circuit board assembly (PCBA) 612, and structural support component 614.


The pump reservoir 602 can hold or store the drug or medicine that can be delivered to a user (e.g., insulin). The pump reservoir 602 can be accessed or filled through the reservoir inlet 604. The reservoir inlet 604 can provide a path for transferring a fluid from outside of the drug delivery device 600 to inside the drug delivery device 600 for storage and subsequent delivery. The drug stored in the pump reservoir 602 can exit the pump reservoir 602 through the reservoir outlet 606 for delivery to the user. The drug delivery device 600 can include a pump for transferring the drug from the reservoir 602 to a user. In various embodiments, a plunger acting in conjunction with the reservoir 602 can operate as a pump to enable the stored fluid to be expelled for delivery to a patient through a fluid path (e.g., as described in relation to the pumps systems 200 and 400). When extracted by operation of the pump, the drug may follow a path from the reservoir 602 to an outlet of the drug delivery device 602 and then on to a patient.


The sensor 608 can be a pressure sensor (e.g., the pressure sensor 202) and can operate and provide the functionality described above. The sensor 608 can be incorporated into the fluid path of the drug delivery device 600 (e.g., incorporated into the reservoir 602). The sensor 608 can be coupled to a sensor assembly or sensor interface 610. The sensor assembly 610 can provide connectivity between the sensor 608 and the PCBA 612. The PCBA 612 can house or contain additional functional components for operating the drug delivery device 600 including, for example, a controller for operating the drug pump to deliver stored fluid from the reservoir 602 to the user. The PCBA 612 can further house or contain components related to user interaction or control components as well as user feedback components including, such as, any of the alarm mechanisms or components described herein. Signals can be transferred bidirectionally between the sensor 608 and the PCBA 612 (and any other components coupled to the PCBA 612) by way of the interface 610. The monitoring component 204 can be integrated across any number of components included in the drug delivery device 600 and can, in various embodiments, include a processor and associated memory, dedicated hardware, or any device capable of executing instructions (e.g., computer executable code, firmware, etc.).


The structural support component 614 can correspond to the structural support component 108 represented in FIGS. 1, 2, and 4. The structural support component 614 can provide mechanical structural support for the reservoir 602 as well as the plunger and fluid path of the drug delivery device 600 and so can include any component of the drug delivery device 600 that supports these components.



FIG. 11 illustrates the drug delivery device 600 depicted in FIG. 6 with a transparent version of the reservoir 602 to reveal additional detail of the drug delivery device 600. As shown in FIG. 11, the drug delivery device 600 includes a plunger 1102 that can be positioned within the reservoir 602. An end portion or stem of the plunger 1102 can extend outside of the reservoir 602. The plunger 1102 can expel the liquid drug from the reservoir 602 by advancing into the reservoir 602. The plunger 1102 can be advanced by a plunger or pump drive mechanism that can be coupled to the plunger 1102 as described above (not illustrated in FIG. 11 for simplicity).



FIG. 11 further illustrates a fluid path component 1104. The fluid path component 1104 can couple the reservoir 602 to a user of the drug delivery device 600. The liquid drug expelled from the reservoir 602 can be provided to the patient by way of the fluid path component 1104. The fluid path component 1104 can correspond to the representation of the fluid path component 106 depicted in FIGS. 1, 2, and 4.



FIGS. 7-10 illustrates various techniques for incorporating a pressure sensor (e.g., the pressure sensor 202) into the fluid path of a pump system—in particular, a pump system included within the drug delivery device 600.



FIG. 7 illustrates a sensor retention clip 702 coupled to the sensor 608 and a pressure transfer membrane 704. The pressure transfer membrane 704 can isolate the sensor 608 from the fluid path—for example, a liquid drug stored in the reservoir 602. The pressure transfer membrane 704 can react to a displacement force caused by, for example, a pumping action to expel a liquid drug from the reservoir 602. The sensor retention clip 702 can help maintain a positioning of the sensor 608 as it responds to (e.g., and monitors and/or measures) changes in pressure that may be caused by any displacement force. A force transfer potting (not shown in FIG. 7 for simplicity) can be used to transfer changes in pressure for measurement by the sensor 608 and can be positioned between the sensor 608 and the membrane 704.



FIG. 8 illustrates the sensor 608 positioned within a pressure sensor installation port 802. The sensor 608, as described above, can have a round shape and can be fitted into the installation port 802 to form a tight fit with the reservoir 602. The sensor 608 can include a portion 804 that extends into the installation port 802. The sensor 608 and portion 804 can be isolated from the fluid path of the drug delivery device 600 by the walls of the reservoir 602 and the sensor 608 and extended portion 804. The sensor 608 and the extended portion 804 can be pressed into an undersized bore forming a portion of the installation port 802 to ensure an air-tight and liquid-tight seal (e.g., a hermetic seal). The engagement of the sensor 608 with the fluid path as shown in FIG. 8 can be considered to be a long engagement press fit. The arrangement shown in FIG. 8 can further include force transfer potting (not shown in FIG. 8 for simplicity) as will be understood by a person of ordinary skill in the art.



FIG. 9 illustrates the sensor 608 positioned within the pressure sensor installation port 802 and an integral radial point seal 902 positioned with the installation port 802. The radial seal 902 can be positioned anywhere along the extended portion 804 and can be molded into the walls of the reservoir 602/installation port 802. The radial seal 902 can further help isolate the sensor 608 from the fluid path of the drug delivery device 600. The arrangement shown in FIG. 9 can further include force transfer potting (not shown in FIG. 9 for simplicity) as will be understood by a person of ordinary skill in the art.



FIG. 10 illustrates the sensor 608 positioned within the pressure sensor installation port 802 and a radial lip seal 1002 and a radial point seal 1004. The radial lip seal 1002 and the radial point seal 1004 can be molded into the walls of the reservoir 602/installation port 802. The sensor 608 and extended portion 804 thereof can be pressed into the installation port 802 and can engage the radial lip seal 1002 and the radial point seal 1004. The radial lip seal 1002 radially extends into an open area of the installation port 802. The radial lip seal 1002 can form a pointed end feature that can bend out of the way when the sensor 608 and extended portion 804 are pressed into the installation port 802. The radial lip seal 1002 provides a further isolating sealing feature. Pressure can cause the seal between the sensor 608, the extended portion 804, and/or the walls of the reservoir 602 to engage the radial lip seal 1002 in a tighter manner, thereby resulting in a better or tighter seal as pressure increases (e.g., as more of the liquid drug is expelled from the reservoir 602). The arrangement shown in FIG. 10 can further include force transfer potting (not shown in FIG. 10 for simplicity) as will be understood by a person of ordinary skill in the art.


In various embodiments, during an operation to provide a drug to a user, when a pump pulse occurs, a sharp rise in pressure can be sensed, followed by a slow decay as the pulse exits a narrow pump cannula of a drug delivery device. By monitoring the pressure spike and the corresponding decay, any of the pump systems (e.g., pump systems 200 or 400) or drug delivery devices described herein can determine if fluid is flowing, or if there is in an occlusion.


Pressure spikes that may occur when a pulse is not being delivered can be due to external effects (e.g., flying, swimming, physiological changes). By comparing pressure changes to the characteristic fluid capacitance, techniques described herein can determine if unexpected under-delivery or over-delivery of the drug has occurred in real time. Further, by comparing delivery conditions to a baseline and non-delivery conditions to the baseline, under-delivery and over-delivery conditions may be detected, as described herein.


The pump systems (e.g., pump systems 200 or 400) or drug delivery devices described herein, including techniques described herein performed by these devices, can provide numerous benefits over conventional drug delivery devices. In particular, the techniques described herein can provide virtual real-time occlusion detection. Further, the techniques can distinguish an occlusion (e.g., a no flow or low flow condition) from an increase in back pressure (e.g., increased resistance with continual flow). Additionally, the techniques described herein can track and log data (e.g., pressure change information) related to excursions from stated altitude or depth specifications.


The following examples pertain to additional further embodiments:


Example 1 is a method comprising determining a first pressure at a start of a delivery operation for a liquid drug, determining a second pressure at an end of the delivery operation for the liquid drug, determining a fluid capacitance value of a fluid path used for the delivery operation of the liquid drug, and determining an intended liquid drug delivery amount, and determining a delivery error amount of the liquid drug based on the first and second pressures, the fluid capacitance value, and the intended liquid drug delivery amount.


Example 2 is an extension of Example 1 or any other example disclosed herein, further comprising determining the first and second pressures based on determining an absolute pressure.


Example 3 is an extension of Example 2 or any other example disclosed herein, further comprising comparing the delivery error amount to one or more thresholds.


Example 4 is an extension of Example 3 or any other example disclosed herein, further comprising determining an over-delivery condition when the delivery error amount is greater than a first threshold.


Example 5 is an extension of Example 4 or any other example disclosed herein, further comprising determining an under-delivery condition when the delivery error amount is less than a second threshold.


Example 6 is an extension of Example 5 or any other example disclosed herein, further comprising providing a first alarm in response to the over-delivery condition and providing a second, different alarm in response to the under-delivery condition.


Example 7 is an extension of Example 6 or any other example disclosed herein, wherein the first and second alarms comprise at least one of an audible, a visual, and a tactile indication.


Example 8 is an extension of Example 7 or any other example disclosed herein, further comprising adjusting an indication of urgency of at least one of the first and second alarms based on a determined severity of the over-delivery condition and the under-delivery condition, respectively.


Example 9 is an extension of Example 6 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds.


Example 10 is an extension of Example 9 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on a de-rating factor based on a determined total amount of delivered liquid drug.


Example 11 is an extension of Example 9 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on a de-rating factor based on a determined unmetabolized excess amount of over-delivered liquid drug.


Example 12 is an extension of Example 9 or any other example disclosed herein, further comprising determining a rate of change of atmospheric pressure.


Example 13 is an extension of Example 12 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on the determined rate of change of the atmospheric pressure.


Example 14 is an extension of Example 9 or any other example disclosed herein, further comprising determining a temperature.


Example 15 is an extension of Example 14 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on the determined temperature.


Example 16 is an extension of Example 1 or any other example disclosed herein, further comprising determining an unintended delivery error amount of the liquid drug during a time outside of the delivery operation of the liquid drug.


Example 17 is an extension of Example 16 or any other example disclosed herein, further comprising comparing the unintended delivery error amount to one or more unintended delivery thresholds.


Example 18 is an extension of Example 17 or any other example disclosed herein, further comprising providing an alarm responsive to comparing the unintended delivery error amount to the one or more unintended delivery thresholds.


Example 19 is an apparatus comprising a reservoir configured to hold a liquid drug, a fluid path component configured to couple the reservoir to a user, a plunger configured to expel the liquid drug from the reservoir for delivery to the user, an absolute pressure sensor configured to detect atmospheric pressure and relative pressure, and a monitoring component configured to determine a delivery error amount during an intended delivery operation and an unintended delivery operation based on the atmospheric pressure and the relative pressure.


Example 20 is an extension of Example 19 or any other example disclosed herein, wherein the plunger is directed to expel the liquid drug from the reservoir during an intended delivery operation and is directed to not expel the liquid drug from the reservoir during an unintended delivery operation.


Example 21 is an extension of Example 20 or any other example disclosed herein, wherein the monitoring component indicates an over-delivery condition when the delivery error amount is greater than a first threshold and wherein the monitoring component indicates an under-delivery condition when the delivery error amount is less than a second, different threshold.


Example 22 is an extension of Example 21 or any other example disclosed herein, wherein the monitoring component is configured to generate an alarm signal based on a determined severity of at least one of the over-delivery condition and the under-delivery condition.


Example 23 is an extension of Example 22 or any other example disclosed herein, wherein the alarm signal comprises at least one of a visual, an audible, and a tactile alert.


Example 24 is an extension of Example 21 or any other example disclosed herein, wherein the monitoring component is configured to dynamically adjust the first and second thresholds.


Example 25 is an extension of Example 24 or any other example disclosed herein, further comprising a temperature sensor, the monitoring component configured to dynamically adjust the first and second thresholds based on at least one of a determined temperature and a de-rating factor based on a determined total amount of delivered liquid drug.


Certain embodiments of the present invention were described above. It is, however, expressly noted that the present invention is not limited to those embodiments, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.

Claims
  • 1. An apparatus, comprising: a reservoir configured to hold a liquid drug;a fluid path component configured to be coupled to the reservoir;a plunger configured to expel the liquid drug from the reservoir for delivery via the fluid path component;a pressure transfer membrane coupled to the reservoir and operable to detect a pressure change within the reservoir;a pressure sensor coupled to the pressure transfer membrane, wherein the pressure sensor is configured to detect atmospheric pressure and relative pressure from the pressure transfer membrane and output signals based on the detected atmospheric pressure and relative pressure;a sensor interface coupled to the pressure sensor and operable to receive the signals output by the pressure sensor based on the detected atmospheric pressure and relative pressure; anda monitoring component coupled to the sensor interface including circuitry, wherein the circuitry is operable to: receive a first signal indicative of a first pressure from the sensor interface;receive a second signal indicative of a second pressure from the sensor interface;determine a delivery error amount of the liquid drug based on the first pressure and the second pressure;actuate an alarm actuator to activate an alarm when a first threshold or a second threshold is passed.
  • 2. The apparatus of claim 1, wherein the pressure transfer membrane is operable to isolate the pressure sensor from the liquid drug.
  • 3. The apparatus of claim 1, wherein the pressure transfer membrane is operable to react to a displacement force caused by a pumping action to expel a liquid drug from the reservoir.
  • 4. The apparatus of claim 1, wherein the plunger is directed to expel the liquid drug from the reservoir during an intended delivery operation and is directed to not expel the liquid drug from the reservoir during an unintended delivery operation.
  • 5. The apparatus of claim 1, wherein: the first pressure is a pressure at a start of a delivery operation for the liquid drug,the second pressure is a pressure at an end of the delivery operation for the liquid drug, andthe circuitry of the monitoring component is configured to: determine a fluid capacitance value of a fluid path used for the delivery operation of the liquid drug based on the first pressure and the second pressure;determine an intended liquid drug delivery amount; anddetermine the delivery error amount of the liquid drug based on the first pressure, the second pressure, the fluid capacitance value, and the intended liquid drug delivery amount.
  • 6. The apparatus of claim 5, wherein the alarm comprises at least one of a visual, an audible, and a tactile alert.
  • 7. The apparatus of claim 1, wherein the monitoring component indicates: an over-delivery condition when the delivery error amount is greater than the first threshold, andan under-delivery condition when the delivery error amount is less than the second threshold.
  • 8. The apparatus of claim 7, wherein the monitoring component is configured to generate the alert-alarm signal based on a determined severity of the over-delivery condition or the under-delivery condition.
  • 9. The apparatus of claim 7, wherein the monitoring component is configured to dynamically adjust the first and second thresholds.
  • 10. The apparatus of claim 7, further comprising: a temperature sensor operable to provide a measure of temperature to the monitoring component, wherein the monitoring component is further configured to dynamically adjust the first and second thresholds based on a measured temperature or a de-rating factor based on a determined total amount of delivered liquid drug.
  • 11. The apparatus of claim 5, wherein the first signal is received at a first point in time and the second signal is received at a second point in time later than when the first signal is received.
  • 12. The apparatus of claim 5, wherein the fluid capacitance value changes in response to effective stiffness of a reservoir containing the liquid drug as the plunger is advanced further into the reservoir by a plunger drive mechanism coupled to the monitoring component.
  • 13. An apparatus, comprising: a reservoir configured to hold a liquid drug;a fluid path component configured to form a fluid path from the reservoir;a plunger configured to expel the liquid drug from the reservoir for delivery of the liquid drug via the fluid path formed by the fluid path component;a pressure sensor installation port adjacent to the reservoir;a pressure sensor operable to fit into the pressure sensor installation port, wherein: the pressure sensor is configured to detect pressure from a pressure transfer membrane and output signals based on the detected pressure of the fluid path, andthe pressure sensor installation port is operable to isolate the pressure sensor from the fluid path;a sensor interface coupled to the pressure sensor and operable to receive to the signals output by the pressure sensor based on the detected pressure; anda monitoring component coupled to the sensor interface including circuitry, wherein the circuitry is operable to:receive a first signal indicative of a first pressure from the sensor interface;receive a second signal indicative of a second pressure from the sensor interface;determine a delivery error amount of the liquid drug based on the first pressure and the second pressure; andactuate an alarm actuator to activate an alarm when a first threshold or a second threshold is passed.
  • 14. The apparatus of claim 13, wherein the pressure sensor further comprises: an extended portion, wherein the extended portion is operable to couple to the pressure sensor installation port to create a hermetic seal.
  • 15. The apparatus of claim 14, further comprising: a radial point seal positioned within the installation port and operable to further isolate the pressure sensor from the fluid path of the reservoir, wherein the radial point seal is positionable along the extended portion.
  • 16. The apparatus of claim 14, further comprising: a radial lip seal positioned within the installation port and forming a pointed end feature that is operable to bend when the pressure sensor and the extended portion are inserted into the installation port.
  • 17. The apparatus of claim 13, wherein the plunger is directed to expel the liquid drug from the reservoir during an intended delivery operation and is directed to not expel the liquid drug from the reservoir during an unintended delivery operation.
  • 18. The apparatus of claim 13, wherein: the first pressure is a pressure at a start of a delivery operation for the liquid drug,the second pressure is a pressure at an end of the delivery operation for the liquid drug, andthe circuitry of the monitoring component is configured to: determine a fluid capacitance value of a fluid path used for the delivery operation of the liquid drug based on the first pressure and the second pressure;determine an intended liquid drug delivery amount; and determine the delivery error amount of the liquid drug based on the first pressure, and the second pressure, the fluid capacitance value, and the intended liquid drug delivery amount.
  • 19. The apparatus of claim 18, wherein the monitoring component indicates an over-delivery condition when the delivery error amount is greater than a first threshold and the monitoring component indicates an under-delivery condition when the delivery error amount is less than the second threshold.
  • 20. The apparatus of claim 19, wherein the monitoring component is configured to generate the alert-alarm signal based on a determined severity of at least one of the over-delivery condition or the under-delivery condition.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/714,496, filed Sep. 25, 2017, which claims the benefit of U.S. Provisional Application No. 62/398,792, filed Sep. 23, 2016, which are incorporated herein by reference in their entirety.

US Referenced Citations (515)
Number Name Date Kind
2797149 Skeggs Jun 1957 A
3631847 Hobbs Jan 1972 A
3634039 Brandy Jan 1972 A
3812843 Wootten et al. May 1974 A
3841328 Jensen Oct 1974 A
3963380 Thomas, Jr. Jun 1976 A
4055175 Clemens et al. Oct 1977 A
4146029 Ellinwood, Jr. Mar 1979 A
4151845 Clemens May 1979 A
4245634 Albisser et al. Jan 1981 A
4368980 Aldred et al. Jan 1983 A
4403984 Ash Sep 1983 A
4464170 Clemens et al. Aug 1984 A
4526568 Clemens et al. Jul 1985 A
4526569 Bernardi Jul 1985 A
4529401 Leslie Jul 1985 A
4559033 Stephen et al. Dec 1985 A
4573968 Parker Mar 1986 A
4633878 Bombardieri Jan 1987 A
4657529 Prince et al. Apr 1987 A
4670007 Wheeldon Jun 1987 A
4743243 Vaillancourt May 1988 A
4755173 Konopka et al. Jul 1988 A
4781688 Thoma et al. Nov 1988 A
4781693 Martinez et al. Nov 1988 A
4854170 Brimhall et al. Aug 1989 A
4886499 Cirelli et al. Dec 1989 A
4900292 Berry et al. Feb 1990 A
4919596 Slate Apr 1990 A
4925444 Orkin et al. May 1990 A
4940527 Kazlauskas et al. Jul 1990 A
4975581 Robinson et al. Dec 1990 A
4976720 Machold et al. Dec 1990 A
4981140 Wyatt Jan 1991 A
4994047 Walker et al. Feb 1991 A
5007286 Malcolm Apr 1991 A
5097834 Skrabal Mar 1992 A
5102406 Arnold Apr 1992 A
5109850 Blanco et al. May 1992 A
5125415 Bell Jun 1992 A
5134079 Cusack Jul 1992 A
5153827 Coutre Oct 1992 A
5165406 Wong Nov 1992 A
5176662 Bartholomew et al. Jan 1993 A
5178609 Ishikawa Jan 1993 A
5207642 Orkin et al. May 1993 A
5237993 Skrabal Aug 1993 A
5257980 Van Antwerp et al. Nov 1993 A
5273517 Barone et al. Dec 1993 A
5299571 Mastrototaro Apr 1994 A
5308982 Ivaldi et al. May 1994 A
5342298 Michaels Aug 1994 A
5377674 Kuestner Jan 1995 A
5380665 Cusack Jan 1995 A
5385539 Maynard Jan 1995 A
5389078 Zalesky Feb 1995 A
5421812 Langley Jun 1995 A
5505709 Funderburk et al. Apr 1996 A
5505828 Wong et al. Apr 1996 A
5535752 Halperin Jul 1996 A
5558640 Pfeiler et al. Sep 1996 A
5569186 Lord et al. Oct 1996 A
5584813 Livingston et al. Dec 1996 A
5609572 Lang Mar 1997 A
5665065 Colman et al. Sep 1997 A
5685859 Kornerup Nov 1997 A
5693018 Kriesel et al. Dec 1997 A
5697899 Hillman et al. Dec 1997 A
5700695 Yassinzadeh et al. Dec 1997 A
5703364 Rosenthal Dec 1997 A
5714123 Sohrab Feb 1998 A
5716343 Kriesel et al. Feb 1998 A
5722397 Eppstein Mar 1998 A
5741228 Lambrecht et al. Apr 1998 A
5746217 Erickson et al. May 1998 A
5755682 Knudson et al. May 1998 A
5758643 Wong et al. Jun 1998 A
5800405 McPhee Sep 1998 A
5800420 Gross et al. Sep 1998 A
5801057 Smart et al. Sep 1998 A
5804048 Wong et al. Sep 1998 A
5817007 Fodgaard et al. Oct 1998 A
5820622 Gross et al. Oct 1998 A
5823951 Messerschmidt Oct 1998 A
5840020 Heinonen et al. Nov 1998 A
5848991 Gross et al. Dec 1998 A
5851197 Marano et al. Dec 1998 A
5858005 Kriesel Jan 1999 A
5865806 Howell Feb 1999 A
5871470 McWha Feb 1999 A
5879310 Sopp et al. Mar 1999 A
5902253 Pfeiffer et al. May 1999 A
5931814 Alex et al. Aug 1999 A
5932175 Knute et al. Aug 1999 A
5947911 Wong et al. Sep 1999 A
5971941 Simons et al. Oct 1999 A
5993423 Choi Nov 1999 A
5997501 Gross et al. Dec 1999 A
6017318 Gauthier et al. Jan 2000 A
6032059 Henning et al. Feb 2000 A
6036924 Simons et al. Mar 2000 A
6040578 Malin et al. Mar 2000 A
6049727 Crothall Apr 2000 A
6050978 Or et al. Apr 2000 A
6058934 Sullivan May 2000 A
6066103 Duchon et al. May 2000 A
6071292 Makower et al. Jun 2000 A
6072180 Kramer et al. Jun 2000 A
6077055 Vilks Jun 2000 A
6090092 Fowles et al. Jul 2000 A
6101406 Hacker et al. Aug 2000 A
6102872 Doneen et al. Aug 2000 A
6115673 Malin et al. Sep 2000 A
6123827 Wong et al. Sep 2000 A
6124134 Stark Sep 2000 A
6126637 Kriesel et al. Oct 2000 A
6128519 Say Oct 2000 A
6142939 Eppstein et al. Nov 2000 A
6143164 Heller et al. Nov 2000 A
6157041 Thomas et al. Dec 2000 A
6161028 Braig et al. Dec 2000 A
6162639 Douglas Dec 2000 A
6196046 Braig et al. Mar 2001 B1
6200287 Keller Mar 2001 B1
6200338 Solomon et al. Mar 2001 B1
6214629 Freitag et al. Apr 2001 B1
6226082 Roe May 2001 B1
6244776 Wiley Jun 2001 B1
6261065 Nayak et al. Jul 2001 B1
6262798 Shepherd et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6271045 Douglas et al. Aug 2001 B1
6280381 Malin et al. Aug 2001 B1
6285448 Kuenstner Sep 2001 B1
6309370 Haim et al. Oct 2001 B1
6312888 Wong et al. Nov 2001 B1
6334851 Hayes et al. Jan 2002 B1
6375627 Mauze et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6402689 Scarantino et al. Jun 2002 B1
6470279 Samsoondar Oct 2002 B1
6475196 Vachon Nov 2002 B1
6477901 Tadigadapa Nov 2002 B1
6484044 Lilienfeld-Toal Nov 2002 B1
6491656 Morris Dec 2002 B1
6512937 Blank et al. Jan 2003 B2
6525509 Petersson et al. Feb 2003 B1
6528809 Thomas et al. Mar 2003 B1
6540672 Simonsen et al. Apr 2003 B1
6546268 Ishikawa et al. Apr 2003 B1
6546269 Kumik Apr 2003 B1
6553841 Blouch Apr 2003 B1
6556850 Braig et al. Apr 2003 B1
6558351 Steil et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6562014 Lin et al. May 2003 B2
6569125 Jepson et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6572545 Knobbe et al. Jun 2003 B2
6574490 Abbink et al. Jun 2003 B2
6575905 Knobbe et al. Jun 2003 B2
6580934 Braig et al. Jun 2003 B1
6618603 Varalli et al. Sep 2003 B2
6633772 Ford et al. Oct 2003 B2
6645142 Braig et al. Nov 2003 B2
6653091 Dunn et al. Nov 2003 B1
6662030 Khalil et al. Dec 2003 B2
6669663 Thompson Dec 2003 B1
6678542 Braig et al. Jan 2004 B2
6699221 Vaillancourt Mar 2004 B2
6718189 Rohrscheib et al. Apr 2004 B2
6721582 Trepagnier et al. Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6740059 Flaherty May 2004 B2
6740072 Starkweather et al. May 2004 B2
6751490 Esenaliev et al. Jun 2004 B2
6758835 Close et al. Jul 2004 B2
6780156 Haueter et al. Aug 2004 B2
6810290 Lebel et al. Oct 2004 B2
6837858 Cunningham et al. Jan 2005 B2
6837988 Leong et al. Jan 2005 B2
6846288 Nagar et al. Jan 2005 B2
6862534 Sterling et al. Mar 2005 B2
6865408 Abbink et al. Mar 2005 B1
6890291 Robinson et al. May 2005 B2
6936029 Mann et al. Aug 2005 B2
6949081 Chance Sep 2005 B1
6958809 Sterling et al. Oct 2005 B2
6989891 Braig et al. Jan 2006 B2
6990366 Say et al. Jan 2006 B2
7008404 Nakajima Mar 2006 B2
7009180 Sterling et al. Mar 2006 B2
7016713 Gardner et al. Mar 2006 B2
7018360 Flaherty et al. Mar 2006 B2
7025743 Mann et al. Apr 2006 B2
7025744 Utterberg et al. Apr 2006 B2
7027848 Robinson et al. Apr 2006 B2
7043288 Davis, III et al. May 2006 B2
7060059 Keith et al. Jun 2006 B2
7061593 Braig et al. Jun 2006 B2
7096124 Sterling et al. Aug 2006 B2
7115205 Robinson et al. Oct 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7139593 Kavak et al. Nov 2006 B2
7139598 Hull et al. Nov 2006 B2
7144384 Gorman et al. Dec 2006 B2
7171252 Scarantino et al. Jan 2007 B1
7190988 Say et al. Mar 2007 B2
7204823 Estes et al. Apr 2007 B2
7248912 Gough et al. Jul 2007 B2
7267665 Steil et al. Sep 2007 B2
7271912 Sterling et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7291107 Hellwig et al. Nov 2007 B2
7291497 Holmes et al. Nov 2007 B2
7303549 Flaherty et al. Dec 2007 B2
7303622 Loch et al. Dec 2007 B2
7303922 Jeng et al. Dec 2007 B2
7354420 Steil et al. Apr 2008 B2
7388202 Sterling et al. Jun 2008 B2
7402153 Steil et al. Jul 2008 B2
7404796 Ginsberg Jul 2008 B2
7429255 Thompson Sep 2008 B2
7460130 Salganicoff Dec 2008 B2
7481787 Gable et al. Jan 2009 B2
7491187 Van Den Berghe et al. Feb 2009 B2
7500949 Gottlieb et al. Mar 2009 B2
7509156 Flanders Mar 2009 B2
7547281 Hayes et al. Jun 2009 B2
7569030 Lebel et al. Aug 2009 B2
7608042 Goldberger et al. Oct 2009 B2
7680529 Kroll Mar 2010 B2
7734323 Blomquist et al. Jun 2010 B2
7766829 Sloan et al. Aug 2010 B2
7785258 Braig et al. Aug 2010 B2
7806854 Damiano et al. Oct 2010 B2
7806886 Kanderian, Jr. et al. Oct 2010 B2
7918825 O'Connor et al. Apr 2011 B2
7946985 Mastrototaro et al. May 2011 B2
7972296 Braig et al. Jul 2011 B2
8221345 Blomquist Jul 2012 B2
8251907 Sterling et al. Aug 2012 B2
8449524 Braig et al. May 2013 B2
8547239 Peatfield Oct 2013 B2
8810394 Kalpin Aug 2014 B2
9061097 Holt et al. Jun 2015 B2
9233204 Booth et al. Jan 2016 B2
9486571 Rosinko Nov 2016 B2
9743224 San Vicente et al. Aug 2017 B2
9980140 Spencer et al. May 2018 B1
10248839 Levy Apr 2019 B2
10335464 Michelich et al. Jul 2019 B1
10583250 Mazlish et al. Mar 2020 B2
10737024 Schmid Aug 2020 B2
10987468 Mazlish et al. Apr 2021 B2
11197964 Sjolund et al. Dec 2021 B2
11260169 Estes Mar 2022 B2
20010021803 Blank et al. Sep 2001 A1
20010034023 Stanton, Jr. Oct 2001 A1
20010034502 Moberg Oct 2001 A1
20010051377 Hammer et al. Dec 2001 A1
20010053895 Vaillancourt Dec 2001 A1
20020010401 Bushmakin et al. Jan 2002 A1
20020010423 Gross et al. Jan 2002 A1
20020016568 Lebel Feb 2002 A1
20020040208 Flaherty Apr 2002 A1
20020123740 Flaherty Sep 2002 A1
20020128543 Leonhardt Sep 2002 A1
20020147423 Burbank et al. Oct 2002 A1
20020155425 Han et al. Oct 2002 A1
20030023148 Lorenz et al. Jan 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030086074 Braig et al. May 2003 A1
20030086075 Braig et al. May 2003 A1
20030090649 Sterling et al. May 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030135388 Martucci et al. Jul 2003 A1
20030144582 Cohen et al. Jul 2003 A1
20030163097 Fleury et al. Aug 2003 A1
20030195404 Knobbe et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030208154 Close Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030216627 Lorenz et al. Nov 2003 A1
20030220605 Bowman, Jr. Nov 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040034295 Salganicoff Feb 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040051368 Caputo et al. Mar 2004 A1
20040064259 Haaland et al. Apr 2004 A1
20040097796 Berman et al. May 2004 A1
20040116847 Wall Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040133166 Moberg Jul 2004 A1
20040147034 Gore et al. Jul 2004 A1
20040171983 Sparks Sep 2004 A1
20040203357 Nassimi Oct 2004 A1
20040204868 Maynard et al. Oct 2004 A1
20040215492 Choi Oct 2004 A1
20040220517 Starkweather et al. Nov 2004 A1
20040241736 Hendee et al. Dec 2004 A1
20040249308 Forssell Dec 2004 A1
20050003470 Nelson et al. Jan 2005 A1
20050020980 Inoue et al. Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050033148 Haueter et al. Feb 2005 A1
20050049179 Davidson et al. Mar 2005 A1
20050065464 Talbot et al. Mar 2005 A1
20050065465 Lebel et al. Mar 2005 A1
20050075624 Miesel Apr 2005 A1
20050105095 Pesach et al. May 2005 A1
20050137573 McLaughlin Jun 2005 A1
20050171503 Van Den Berghe et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050192494 Ginsberg Sep 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050203461 Flaherty Sep 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20050261562 Zhou Nov 2005 A1
20050261660 Choi Nov 2005 A1
20050277912 John Dec 2005 A1
20060009727 O'Mahony et al. Jan 2006 A1
20060079809 Goldberger et al. Apr 2006 A1
20060100494 Kroll May 2006 A1
20060134323 O'Brien Jun 2006 A1
20060167350 Monfre et al. Jul 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060189925 Gable et al. Aug 2006 A1
20060189926 Hall et al. Aug 2006 A1
20060197015 Sterling et al. Sep 2006 A1
20060200070 Callicoat et al. Sep 2006 A1
20060204535 Johnson Sep 2006 A1
20060229531 Goldberger et al. Oct 2006 A1
20060253085 Geismar et al. Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060270983 Lord Nov 2006 A1
20060276771 Galley et al. Dec 2006 A1
20060282290 Flaherty et al. Dec 2006 A1
20070016127 Staib et al. Jan 2007 A1
20070060796 Kim Mar 2007 A1
20070060869 Tolle et al. Mar 2007 A1
20070060872 Hall et al. Mar 2007 A1
20070083160 Hall et al. Apr 2007 A1
20070106135 Sloan et al. May 2007 A1
20070116601 Patton May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070129690 Rosenblatt et al. Jun 2007 A1
20070142720 Ridder et al. Jun 2007 A1
20070173761 Kanderian et al. Jul 2007 A1
20070173974 Lin Jul 2007 A1
20070179352 Randlov et al. Aug 2007 A1
20070191716 Goldberger et al. Aug 2007 A1
20070197163 Robertson Aug 2007 A1
20070225675 Robinson et al. Sep 2007 A1
20070244381 Robinson et al. Oct 2007 A1
20070249007 Rosero Oct 2007 A1
20070264707 Liederman et al. Nov 2007 A1
20070282269 Carter et al. Dec 2007 A1
20070287985 Estes et al. Dec 2007 A1
20070293843 Ireland et al. Dec 2007 A1
20080051764 Dent et al. Feb 2008 A1
20080058625 McGarraugh et al. Mar 2008 A1
20080065050 Sparks et al. Mar 2008 A1
20080071157 McGarraugh et al. Mar 2008 A1
20080071158 McGarraugh et al. Mar 2008 A1
20080078400 Martens et al. Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080132880 Buchman Jun 2008 A1
20080161664 Mastrototaro et al. Jul 2008 A1
20080172026 Blomquist Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080200838 Goldberger et al. Aug 2008 A1
20080206067 De Corral Aug 2008 A1
20080208113 Damiano et al. Aug 2008 A1
20080214919 Harmon et al. Sep 2008 A1
20080228056 Blomquist et al. Sep 2008 A1
20080249386 Besterman et al. Oct 2008 A1
20080269585 Ginsberg Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080287906 Burkholz et al. Nov 2008 A1
20090006061 Thukral et al. Jan 2009 A1
20090018406 Yodfat et al. Jan 2009 A1
20090030398 Yodfat et al. Jan 2009 A1
20090036753 King Feb 2009 A1
20090043240 Robinson et al. Feb 2009 A1
20090054753 Robinson et al. Feb 2009 A1
20090069743 Krishnamoorthy et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090099521 Gravesen et al. Apr 2009 A1
20090131861 Braig et al. May 2009 A1
20090156922 Goldberger et al. Jun 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090228214 Say et al. Sep 2009 A1
20090318791 Kaastrup Dec 2009 A1
20090326343 Gable et al. Dec 2009 A1
20100057042 Hayter Mar 2010 A1
20100114026 Karratt et al. May 2010 A1
20100121170 Rule May 2010 A1
20100137784 Cefai et al. Jun 2010 A1
20100152658 Hanson et al. Jun 2010 A1
20100211003 Sundar Aug 2010 A1
20100295686 Sloan et al. Nov 2010 A1
20110054390 Searle et al. Mar 2011 A1
20110054399 Chong et al. Mar 2011 A1
20110124996 Reinke et al. May 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110160652 Yodat et al. Jun 2011 A1
20110178472 Cabiri Jul 2011 A1
20110190694 Lanier, Jr. Aug 2011 A1
20110202005 Yodfat Aug 2011 A1
20110218495 Remde Sep 2011 A1
20110230833 Landman et al. Sep 2011 A1
20110251509 Beyhan et al. Oct 2011 A1
20110316562 Cefai et al. Dec 2011 A1
20120003935 Lydon et al. Jan 2012 A1
20120010594 Holt et al. Jan 2012 A1
20120030393 Ganesh et al. Feb 2012 A1
20120053556 Lee Mar 2012 A1
20120078067 Kovatchev et al. Mar 2012 A1
20120078161 Masterson et al. Mar 2012 A1
20120078181 Smith Mar 2012 A1
20120101451 Boit Apr 2012 A1
20120190955 Rao et al. Jul 2012 A1
20120203178 Tverskoy Aug 2012 A1
20120226259 Yodfat et al. Sep 2012 A1
20120238851 Kamen et al. Sep 2012 A1
20120271655 Knobel et al. Oct 2012 A1
20120277668 Chawla Nov 2012 A1
20120282111 Nip Nov 2012 A1
20120295550 Wilson et al. Nov 2012 A1
20130030358 Yodfat et al. Jan 2013 A1
20130178791 Javitt Jul 2013 A1
20130253472 Cabiri Sep 2013 A1
20130296823 Melker et al. Nov 2013 A1
20130317753 Kamen Nov 2013 A1
20130338576 O'Connor Dec 2013 A1
20140005633 Finan Jan 2014 A1
20140066886 Roy et al. Mar 2014 A1
20140074033 Sonderegger et al. Mar 2014 A1
20140128839 Dilanni et al. May 2014 A1
20140135880 Baumgartner et al. May 2014 A1
20140146202 Boss et al. May 2014 A1
20140200426 Taub et al. Jul 2014 A1
20140230021 Birtwhistle et al. Aug 2014 A1
20140276554 Finan et al. Sep 2014 A1
20140276556 Saint Sep 2014 A1
20140309615 Mazlish Oct 2014 A1
20140316379 Sonderegger et al. Oct 2014 A1
20140325065 Birtwhistle et al. Oct 2014 A1
20150120317 Mayou et al. Apr 2015 A1
20150134265 Kohlbrecher et al. May 2015 A1
20150165119 Palerm et al. Jun 2015 A1
20150173674 Hayes et al. Jun 2015 A1
20150217052 Keenan et al. Aug 2015 A1
20150217053 Booth et al. Aug 2015 A1
20150265767 Vazquez et al. Sep 2015 A1
20150351671 Vanslyke et al. Dec 2015 A1
20150366945 Greene Dec 2015 A1
20160015891 Papiorek Jan 2016 A1
20160038673 Morales Feb 2016 A1
20160038689 Lee et al. Feb 2016 A1
20160051749 Istoc Feb 2016 A1
20160089494 Guerrini Mar 2016 A1
20160175520 Palerm et al. Jun 2016 A1
20160228641 Gescheit et al. Aug 2016 A1
20160243318 Despa et al. Aug 2016 A1
20160256087 Doyle, III Sep 2016 A1
20160302054 Kimura et al. Oct 2016 A1
20160331310 Kovatchev Nov 2016 A1
20160354543 Cinar et al. Dec 2016 A1
20170049386 Abraham et al. Feb 2017 A1
20170143900 Rioux et al. May 2017 A1
20170173261 O'Connor Jun 2017 A1
20170189625 Cirillo Jul 2017 A1
20170281877 Marlin et al. Oct 2017 A1
20170296746 Chen et al. Oct 2017 A1
20170311903 Davis et al. Nov 2017 A1
20170348482 Duke et al. Dec 2017 A1
20180036495 Searle Feb 2018 A1
20180040255 Freeman et al. Feb 2018 A1
20180075200 Davis et al. Mar 2018 A1
20180075201 Davis et al. Mar 2018 A1
20180075202 Davis et al. Mar 2018 A1
20180092576 Ambrosio Apr 2018 A1
20180126073 Wu et al. May 2018 A1
20180169334 Grosman et al. Jun 2018 A1
20180200434 Mazlish et al. Jul 2018 A1
20180200438 Mazlish et al. Jul 2018 A1
20180200441 Desborough et al. Jul 2018 A1
20180204636 Edwards Jul 2018 A1
20180289891 Finan et al. Oct 2018 A1
20180296757 Finan et al. Oct 2018 A1
20180342317 Skirble et al. Nov 2018 A1
20180369479 Hayter et al. Dec 2018 A1
20190076600 Grosman et al. Mar 2019 A1
20190240403 Palerm et al. Aug 2019 A1
20190290844 Monirabbasi et al. Sep 2019 A1
20190336683 O'Connor et al. Nov 2019 A1
20190336684 O'Connor et al. Nov 2019 A1
20190348157 Booth et al. Nov 2019 A1
20200046268 Patek et al. Feb 2020 A1
20200101222 Lintereur et al. Apr 2020 A1
20200101223 Lintereur Apr 2020 A1
20200101225 O'Connor et al. Apr 2020 A1
20200219625 Kahlbaugh Jul 2020 A1
20200342974 Chen et al. Oct 2020 A1
20210050085 Hayter et al. Feb 2021 A1
20210098105 Lee et al. Apr 2021 A1
20220023536 Graham et al. Jan 2022 A1
Foreign Referenced Citations (90)
Number Date Country
2015200834 Mar 2015 AU
1297140 May 2001 CN
19756872 Jul 1999 DE
0341049 Nov 1989 EP
0496305 Jul 1992 EP
0549341 Jun 1993 EP
1491144 Dec 2004 EP
1571582 Sep 2005 EP
0801578 Jul 2006 EP
2666520 Oct 2009 EP
2139382 Jan 2010 EP
2397181 Dec 2011 EP
2695573 Feb 2014 EP
2830499 Feb 2015 EP
2897071 May 2019 EP
3607985 Feb 2020 EP
2443261 Apr 2008 GB
51125993 Nov 1976 JP
02131777 May 1990 JP
2004283378 Oct 2004 JP
2017525451 Sep 2017 JP
2018153569 Oct 2018 JP
2019525276 Sep 2019 JP
200740148 Oct 2007 TW
M452390 May 2013 TW
9800193 Jan 1998 WO
9956803 Nov 1999 WO
0030705 Jun 2000 WO
0032258 Jun 2000 WO
0172354 Oct 2001 WO
2002015954 Feb 2002 WO
0243866 Jun 2002 WO
02082990 Oct 2002 WO
03016882 Feb 2003 WO
03039362 May 2003 WO
03045233 Jun 2003 WO
2004043250 May 2004 WO
04092715 Oct 2004 WO
2005051170 Jun 2005 WO
2005082436 Sep 2005 WO
05110601 Nov 2005 WO
2006053007 May 2006 WO
2007064835 Jun 2007 WO
2007078937 Jul 2007 WO
2008024810 Feb 2008 WO
2008029403 Mar 2008 WO
2008133702 Nov 2008 WO
2009045462 Apr 2009 WO
2009049252 Apr 2009 WO
2009066287 May 2009 WO
2009066288 May 2009 WO
2009098648 Aug 2009 WO
2009134380 Nov 2009 WO
2010053702 May 2010 WO
2010132077 Nov 2010 WO
2010138848 Dec 2010 WO
2010147659 Dec 2010 WO
2011095483 Aug 2011 WO
2012045667 Apr 2012 WO
2012108959 Aug 2012 WO
2012134588 Oct 2012 WO
2013078200 May 2013 WO
2013134486 Sep 2013 WO
20130149186 Oct 2013 WO
2013177565 Nov 2013 WO
2013182321 Dec 2013 WO
2014194183 Dec 2014 WO
2015056259 Apr 2015 WO
2015081337 Jun 2015 WO
2015187366 Dec 2015 WO
2016004088 Jan 2016 WO
2016041873 Mar 2016 WO
2016089702 Jun 2016 WO
2016141082 Sep 2016 WO
2016161254 Oct 2016 WO
2017091624 Jun 2017 WO
2017105600 Jun 2017 WO
2017184988 Oct 2017 WO
2017205816 Nov 2017 WO
2018009614 Jan 2018 WO
2018067748 Apr 2018 WO
2018120104 Jul 2018 WO
2018136799 Jul 2018 WO
2018204568 Nov 2018 WO
2019077482 Apr 2019 WO
2019094440 May 2019 WO
2019213493 Nov 2019 WO
2019246381 Dec 2019 WO
2020081393 Apr 2020 WO
2021011738 Jan 2021 WO
Non-Patent Literature Citations (93)
Entry
US 5,954,699 A, 09/1999, Jost et al. (withdrawn)
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/052125, dated Aug. 12, 2020, 15 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/050332, dated Sep. 12, 2020, 12 pages.
European Patent Office, “Notification of Transmittal of the ISR and the Written Opinion of the International Searching Authority, or the Declaration,” in PCT Application No. PCT/GB2015/050248, dated Jun. 23, 2015, 12 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/051027, dated Jan. 7, 2022, 16 pages.
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/052372, dated Jan. 26, 2022, 15 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/046607, dated Jan. 31, 2022, 20 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/055745, dated Feb. 14, 2022, 13 pages.
European Search Report for the European Patent Application No. 21168591.2, dated Oct. 13, 2021, 4 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/041954, dated Oct. 25, 2021, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/047771, dated Dec. 22, 2021, 11 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/052855, dated Dec. 22, 2021, 11 pages.
Unger, Jeff, et al., “Glucose Control in the Hospitalized Patient,” Emerg. Med 36(9):12-18 (2004).
Glucommander FAQ downloaded from https://adaendo.com/GlucommanderFAQ.html on Mar. 16, 2009.
Finfer, Simon & Heritier, Stephane. (2009). The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 11. 46-57.
Letters to the Editor regarding “Glucose Control in Critically III Patients,” N Engl J Med 361: 1, Jul. 2, 2009.
“Medtronic is Leading a Highly Attractive Growth Market,” Jun. 2, 2009.
Davidson, Paul C., et al. “Glucommander: An Adaptive, Computer-Directed System for IV Insulin Shown to be Safe, Simple, and Effective in 120,618 Hours of Operation,” Atlanta Diabetes Associates presentation Nov. 16, 2003.
Davidson, Paul C., et al. “Pumpmaster and Glucommander,” presented at the MiniMed Symposium, Atlanta GA, Dec. 13, 2003.
Kanji S., et al. “Reliability of point-of-care testing for glucose measurement in critically ill adults,” Critical Care Med, vol. 33, No. 12, pp. 2778-2785, 2005.
Krinsley James S., “Severe hypoglycemia in critically ill patients: Risk factors and outcomes,” Critical Care Med, vol. 35, No. 10, pp. 1-6, 2007.
International Searching Authority, Invitation to Pay Additional Fees, International Application No. PCT/US2006/004929, dated Jul. 27, 2006.
Farkas et al. ““Single-Versus Triple-Lumen Central Catheter-Related Sepsis: A Prospective Randomized Study in a Critically III Population”” The American Journal of Medicine Sep. 1992vol. 93 p. 277-282.
Davidson, Paul C., et al., A computer-directed intravenous insulin system shown to be safe, simple,and effective in 120,618 h of operation. Diabetes Care, vol. 28, No. 10, Oct. 2005, pp. 2418-2423.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/016283, dated Jun. 2, 2021, 15 pages.
Gorke, A. “Microbial contamination of haemodialysis catheter connections.” EDTNA/ERCA journal (English ed.) vol. 31,2 (2005): 79-84. doi:10.1111/j.1755-6686.2005.tb00399.x.
Lovich et al. “Central venous catheter infusions: A laboratory model shows large differences in drug delivery dynamics related to catheter dead volume” Critical Care Med 2007 vol. 35, No. 12.
Van Den Berghe, Greet, M.D., Ph.D., et al., Intensive Insulin Therapy in Critically III Patients, The New England Journal of Medicine, vol. 345, No. 19, Nov. 8, 2001, pp. 1359-1367.
Templeton et al., “Multilumen Central Venous Catheters Increase Risk for Catheter-Related Bloodstream Infection: Prospective Surveillance Study” Infection 2008; 36: 322-327.
Wilson, George S., et al., Progress toward the Development of an Implantable Sensor for Glucose, Clin. Chem., vol. 38, No. 9, 1992, pp. 1613-1617.
Yeung et al. “Infection Rate for Single Lumen v Triple Lumen Subclavian Catheters” Infection Control and Hospital Epidemiology, vol. 9, No. 4 (Apr. 1988) pp. 154-158 The University of Chicago Press.
International Search Report and Written Opinion, International Application No. PCT/US2010/033794 dated Jul. 16, 2010.
International Search Report and Written Opinion in PCT/US2008/079641 dated Feb. 25, 2009.
Berger, ““Measurement of Analytes in Human Serum and Whole Blood Samples by Near-Infrared Raman Spectroscopy,”” Ph.D. Thesis, Massachusetts Institute of Technology, Chapter 4, pp. 50-73, 1998.
Berger, “An Enhanced Algorithm for Linear Multivariate Calibration,” Analytical Chemistry, vol. 70, No. 3, pp. 623-627, Feb. 1, 1998.
Billman et al., “Clinical Performance of an In line Ex-Vivo Point of Care Monitor: A Multicenter Study,” Clinical Chemistry 48: 11, pp. 2030-2043, 2002.
Widness et al., “Clinical Performance on an In-Line Point-of-Care Monitor in Neonates”; Pediatrics, vol. 106, No. 3, pp. 497-504, Sep. 2000.
Finkielman et al., “Agreement Between Bedside Blood and Plasma Glucose Measurement in the ICU Setting” retrieved from http://www.chestjournal.org; CHEST/127/5/May 2005.
Glucon Critical Care Blood Glucose Monitor; Glucon; retrieved from http://www.glucon.com.
Fogt, et al., “Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator)”; Clinical Chemistry, vol. 24, No. 8, pp. 1366-1372, 1978.
Vonach et al., “Application of Mid-Infrared Transmission Spectrometry to the Direct Determination of Glucose in Whole Blood,” Applied Spectroscopy, vol. 52, No. 6, 1998, pp. 820-822.
Muniyappa et al., “Current Approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage,” AJP-Endocrinol Metab, vol. 294, E15-E26, first published Oct. 23, 2007.
R Anthony Shaw, et al., “Infrared Spectroscopy in Clinical and Dianostic Analysis,” Encyclopedia of Analytical Chemistry, ed. Robert A. Meyers, John Wiley & Sons, Ltd., pp. 1-20, 2000.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2019/053603, dated Apr. 8, 2021, 9 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2019/053603, dated Jan. 7, 2020, 16 pages.
Dassau et al., “Detection of a meal using continuous glucose monitoring: Implications for an artificial [beta]-cell.” Diabetes Care, American Diabetes Association, Alexandria, VA, US, 31(2):295-300 (2008).
Cameron et al., “Probabilistic Evolving Meal Detection and Estimation of Meal Total Glucose Appearance Author Affiliations”, J Diabetes Sci and Tech.Vol., Diabetes Technology Society ;(5):1022-1030 (2009).
Lee et al., “A closed-loop artificial pancreas based on model predictive control: Human-friendly identification and automatic meal disturbance rejection”, Biomedical Signal Processing and Control, Elsevier, Amsterdam, NL, 4 (4):1746-8094 (2009).
International Search Report and Written Opinion for the IntemationalPatent Application No. PCT/US2021/018297, dated May 18, 2021, 18 pages.
An Emilia Fushimi: “Artificial Pancreas: Evaluating the ARG Algorithm Without Meal Announcement”, Journal of Diabetes Science and Technology Diabetes Technology Society, Mar. 22, 2019, pp. 1025-1043.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017441, dated May 25, 2021, 12 pages.
International Search Report and Written Opinion for the IntemationalPatent Application No. PCT/US2021/017664, dated May 26, 2021, 16 pages.
Mirko Messori et al: “Individualized model predictive control for the artificial pancreas: In silico evaluation of closed-loop glucose control”, IEEE Control Systems, vol. 38, No. 1, Feb. 1, 2018, pp. 86-104.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017662, dated May 26, 2021, 14 pages.
Anonymous: “Reservoir Best Practice and Top Tips” Feb. 7, 2016, URL: https://www.medtronic-diabetes.co.uk/blog/reservoir-best-practice-and-top-tips, p. 1.
Gildon Bradford: “InPen Smart Insulin Pen System: Product Review and User Experience” Diabetes Spectrum, vol. 31, No. 4, Nov. 15, 2018, pp. 354-358.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/016050, dated May 27, 2021, 16 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/065226, dated May 31, 2021, 18 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017659, dated May 31, 2021, 13 pages.
Montaser Eslam et al., “Seasonal Local Models for Glucose Prediction in Type 1 Diabetes”, IEE Journal of Biomedical and Health Informatics, IEEE, Piscataway, NJ, USA, vol. 24, No. 7, Jul. 2020, pp. 2064-2072.
Samadi Sediqeh et al., “Automatic Detection and Estimation of Unannouced Meals for Multivariable Artificial Pancreas System”, Diabetis Technology & Therapeutics, vol. 20m No. 3, Mar. 1, 2018, pp. 235-246.
Samadi Sediqeh et al., “Meal Detection and Carbohydrate Estimation Using Continuous Glucose Sensor Data” IEEE Journal of Biomedical and Health Informatics, IEEE, Piscataway, NJ, USA, vol. 21, No. 3, May 1, 2017, pp. 619-627.
Khodaei et al., “Physiological Closed-Loop Contol (PCLC) Systems: Review of a Modern Frontier in Automation”, IEEE Access, IEEE, USA, vol. 8, Jan. 20, 2020, pp. 23965-24005.
E. Atlas et al., “MD-Logic Artificial Pancreas System: A pilot study in adults with type 1 diabetes”, Diabetes Care, vol. 33, No. 5, Feb. 11, 2010, pp. 1071-1076.
Anonymous: “Fuzzy control system”, Wikipedia, Jan. 10, 2020. URL: https://en.wikipedia.org/wlindex.php?title=Fuzzy_control_system&oldid=935091190 Retrieved: May 25, 2021.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/022694, dated Jun. 25, 2021, 13 pages.
International Search Report and Written Opinion for the Application No. PCT/US2017/015601, dated May 16, 2017, 12 pages.
International Search Report and Written Opinion for the Application No. PCT/US2018/018901, dated Aug. 6, 2018, 12 pages.
International Search Report and Written Opinion for Application No. PCT/US2018/052467, dated Jan. 4, 2019, 13 pages.
“How to Create a QR Code that Deep Links to Your Mobile App”, Pure Oxygen Labs, web<https://pureoxygenlabs.com/how-to-create-a-qr-codes-that-deep-link-to-your-mobile-app/>. Year:2017.
“Read NFC Tags with an iPHone App on iOS 11”, GoToTags, Sep. 11, 2017, web <https://gototags.com/blog/read-nfc-tags-with-an-iphone-app-on-ios-11/>. (Year:2017).
International Search Report and Written Opinion for International Application No. PCT/US2016/063350, dated Mar. 27, 2017, 9 pages.
PCT International Search Report and Written Opinion dated Apr. 29, 2015, received in corresponding PCT Application No. PCT/US16/18452, 9 pages.
International Preliminary Report on Patentability dated Aug. 31, 2017, issued in PCT Patent Application No. PCT/US2016/018452, 7 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/013470, dated May 6, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/013473, dated May 6, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/019079, dated Jun. 2, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/018453, dated Jun. 2, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/018700, dated Jun. 7, 2022, 13 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019080, dated Jun. 7, 2022, 14 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019664, dated Jun. 7, 2022, 14 pages.
Herrero Pau et al: “Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator-in silicoevaluation under intra-day variability”, Computer Methods and Programs in Biomedicine, Elsevier, Amsterdam, NL, vol. 146, Jun. 1, 2017 (Jun. 1, 2017), pp. 125-131, XP085115607, ISSN: 0169-2607, DOI:10.1016/J.CMPB.2017.05.010.
Herrero Pau Ei Al: “Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal polus calculator-in silicoevaluation under intra-day variability”, Computer Methods and Programs in Biomedicine, Elsevier, Amsterdam, Nl, vol. 146, Jun. 1, 2017 (2017-06-01), pp. 125-131, XP085115607, Ssn: 0169-2607, D0l:10.1016/J.CMPB.2017.05.010.
Marie Aude Qemerais: “Preliminary Evaluation of a New Semi-Closed-Loop Insulin Therapy System over the prandial period in Adult Patients with type I diabetes: the WP6. 0 Diabeloop Study”, Journal of Diabetes Science and Technology Diabetes Technology Society Reprints and permissions, Jan. 1, 2014, p. 1177-1184, Retrieved from the Internet: URL:http://journals.sagepub.com/doi/pdf/10.1177/1932296814545668 [retrieved on Jun. 6, 2022] chapter “Functioning of the Algorithm” chapter “Statistical Analysis” p. 1183, left-hand col. line 16- line 23.
Anonymous: “Kernel density estimation”, Wikipedia, Nov. 13, 2020 (Nov. 13, 2020), pp. 1-12, XP055895569, Retrieved from the Internet: URL:https://en.wikipedia.org/w/index.php?title=Kemnel_density_estimation&oldid=988508333 [retrieved on Jun. 6, 2022].
Anonymous: “openaps / oref0 /lib/determine-basal-js”, openaps repository, Nov. 9, 2019 (Nov. 9, 2019), pp. 1-17, XP055900283, Retrieved from the Internet: URL:https://github.com/openaps/oref0/blob/master/lib/determine-basal/determine-basal.js [retrieved on Jun. 6, 2022] line 116-line 118, line 439-line 446.
Anonymous: “AndroidAPS screens”, AndroidAPS documentation, Oct. 4, 2020 (Oct. 4, 2020), pp. 1-12, XP055894824, Retrieved from the Internet: URL:https://github.com/openaps/AndroidAPSdocs/blob/25d8acf8b28262b411b34f416f173ac0814d7e14/docs/EN/Getting-Started/Screenshots.md [retrieved on Jun. 6, 2022].
Kozak Milos et al: “Issue #2473 of AndroidAPS”, MilosKozak / AndroidAPS Public repository, Mar. 4, 2020 (Mar. 4, 2020), pp. 1-4, XP055900328, Retrieved from the Internet: URL:https://github.com/MilosKozak/AndroidAPS/issues/2473 [retrieved on Jun. 6, 2022].
Medication Bar Code System Implementation Planning Section I: A Bar Code Primer for Leaders, Aug. 2013.
Medication Bar Code System Implementation Planning Section II: Building the Case for Automated Identification of Medications, Aug. 2013.
Villareal et al. (2009) in: Distr. Comp. Art. Intell. Bioninf. Soft Comp. Amb. Ass. Living; Int. Work Conf. Art. Neural Networks (IWANN) 2009, Lect. Notes Comp. Sci. vol. 5518; S. Omatu et al. (Eds.), pp. 870-877.
Fox, Ian G.; Machine Learning for Physiological Time Series: Representing and Controlling Blood Glucose for Diabetes Management; University of Michigan. ProQuest Dissertations Publishing, 2020. 28240142. (Year: 2020).
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/012896, dated Apr. 22, 2022, 15 pages.
Related Publications (1)
Number Date Country
20200338264 A1 Oct 2020 US
Provisional Applications (1)
Number Date Country
62398792 Sep 2016 US
Continuations (1)
Number Date Country
Parent 15714496 Sep 2017 US
Child 16884802 US